NervGen Pharma (NGENF) News Today → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free NGENF Stock Alerts $1.62 +0.17 (+11.72%) (As of 05/17/2024 05:34 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 8:42 AM | finance.yahoo.comNervGen Pharma Reports Q1 2024 Financial Results and Operational UpdatesApril 20, 2024 | finance.yahoo.comNervGen Pharma Corp. (NGENF)April 17, 2024 | finance.yahoo.comNervGen Pharma Reports 2023 Year-End Financial Results and Operational UpdatesMarch 28, 2024 | finance.yahoo.comNervGen Completes $23 Million Bought Deal FinancingMarch 22, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - NGENMarch 21, 2024 | finance.yahoo.comNERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERINGFebruary 15, 2024 | finance.yahoo.comNervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord InjuryNovember 9, 2023 | msn.comNervGen Pharma GAAP EPS of -$0.07November 8, 2023 | finance.yahoo.comNeuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy KawasakiNovember 4, 2023 | morningstar.comNervGen Pharma Corp Ordinary Shares NGENFSeptember 25, 2023 | finance.yahoo.comNervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord InjurySeptember 11, 2023 | finance.yahoo.comNervGen Pharma to Present at 2023 International Spinal Research Trust Network MeetingSeptember 5, 2023 | finance.yahoo.comNervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 22, 2023 | finance.yahoo.comNervGen Pharma to Present on its Drug Candidate NVG-291 and Spinal Cord Injury at Investor ConferenceAugust 8, 2023 | finance.yahoo.comNervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB ApprovalJune 27, 2023 | finance.yahoo.comNervGen Pharma to Receive More than US$3 Million from Wings for Life to Support Upcoming Clinical Study in Spinal Cord InjuryJune 20, 2023 | finance.yahoo.comNervGen Pharma to Present at Upcoming Investor ConferencesMay 15, 2023 | finanznachrichten.deNervGen Pharma Corp.: NervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291May 15, 2023 | finance.yahoo.comNervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291April 14, 2023 | bizjournals.comRaleigh/Durham Pharmaceuticals NewsApril 10, 2023 | finance.yahoo.comNervGen Pharma Appoints Michael Kelly as President & Chief Executive OfficerMarch 30, 2023 | finance.yahoo.comNervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023March 22, 2023 | ca.finance.yahoo.comNervGen Pharma Corp. (NGEN.V)February 14, 2023 | finance.yahoo.comNervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291January 31, 2023 | seekingalpha.comNGEN:CA NervGen Pharma Corp.January 10, 2023 | benzinga.comNervGen Pharma Stock (OTC:NGENF), Quotes and News SummaryNovember 17, 2022 | finance.yahoo.comNervGen Pharma Announces Composition of Matter Patent for NVG-291 Granted by the US Patent and Trade OfficeNovember 14, 2022 | finance.yahoo.comNervGen Pharma Completes Dosing in Its Third Multiple Ascending Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q3 2022 ResultsOctober 25, 2022 | finance.yahoo.comNervGen Pharma Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291September 12, 2022 | finance.yahoo.comNervGen Pharma Announces Appointment of Dr. Matvey Lukashev as Vice President, Research and Preclinical DevelopmentSeptember 8, 2022 | finance.yahoo.comHas The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?September 8, 2022 | finance.yahoo.comNervGen Pharma Presenting at Upcoming Military Health System Research Symposium and the 61st International Spinal Cord Society Annual Scientific MeetingAugust 14, 2022 | seekingalpha.comNervGen Pharma (NGENF) Investor Presentation - SlideshowAugust 10, 2022 | finance.yahoo.comNervGen Pharma Reports Second Quarter 2022 Results and Provides Corporate UpdateAugust 2, 2022 | finance.yahoo.comNervGen Presenting Study Design for Upcoming Phase 1b/2a in Alzheimer's Disease at the 2022 Alzheimer's Association International ConferenceJuly 28, 2022 | finance.yahoo.comNervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve UniversityJuly 14, 2022 | finance.yahoo.comNervGen Pharma Closes US$15MM Private Placement and Appoints Dr. Adam Rogers to Board of DirectorsJuly 11, 2022 | finance.yahoo.comNervGen Pharma Provides Update on Closing of Private PlacementJuly 7, 2022 | benzinga.comNervGen Pharma (OTC:NGENF), Short Interest ReportJune 30, 2022 | finance.yahoo.comNervGen Pharma Corp. Announces US$15MM Non-Brokered Private PlacementJune 2, 2022 | finanznachrichten.deNervGen Pharma Corp.: NervGen Pharma Grants Stock OptionsMay 25, 2022 | finanznachrichten.deNERVGEN PHARMA CORPMay 16, 2022 | finance.yahoo.comNervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)May 12, 2022 | finance.yahoo.comNervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 ResultsMarch 31, 2022 | finance.yahoo.comNervGen Presenting Interim Phase 1 Clinical Trial Data for NVG-291 at the 2022 American Academy of Neurology Annual MeetingMarch 23, 2022 | finance.yahoo.comNervGen Pharma to Present at 2022 Virtual Growth Conference Presented by Maxim GroupMarch 15, 2022 | seekingalpha.comNervGen Pharma gets safety panel nod to advance in phase 1 trial of NVG-291March 15, 2022 | finance.yahoo.comNervGen Pharma Receives Approval from Safety Review Committee to Proceed to Second Cohort in Multiple Ascending Dose Portion of Phase 1 Clinical Trial of NVG-291March 3, 2022 | finance.yahoo.comWe're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn RateMarch 1, 2022 | finanznachrichten.deNervGen Pharma Corp.: NervGen Pharma Reports 2021 Year End Results and Provides Update on Phase 1 Study Get NervGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NGENF and its competitors with MarketBeat's FREE daily newsletter. Email Address The CHIPS Act Motherlode (Ad)If you haven’t heard yet, the CHIPS Act is the US government pouring $280 BILLION into the manufacturing of US semiconductors. A lot of companies will make a fortune from this. Click here to see my #1 investment for 2024. NGENF Media Mentions By Week NGENF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NGENF News Sentiment▼0.400.42▲Average Medical News Sentiment NGENF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NGENF Articles This Week▼10▲NGENF Articles Average Week Get NervGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NGENF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CYBN News Today LIAN News Today ANIX News Today IOBT News Today CLSD News Today MRMD News Today BLUA News Today GNLX News Today ETON News Today ALUR News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:NGENF) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NervGen Pharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
